Strategies for targeting undruggable targets.
Zhang G, Zhang J, Gao Y, Li Y, Li Y.
Expert Opin Drug Discov. 2022 Jan;17(1):55-69. doi: 10.1080/17460441.2021.1969359. Epub 2021 Aug 30.
Targeted Drug Delivery: Trends and Perspectives.
Ashique S, Sandhu NK, Chawla V, Chawla PA.
Curr Drug Deliv. 2021;18(10):1435-1455. doi: 10.2174/1567201818666210609161301.
G protein-coupled receptors (GPCRs): advances in structures, mechanisms, and drug discovery.
Zhang M, Chen T, Lu X, Lan X, Chen Z, Lu S.
Signal Transduct Target Ther. 2024 Apr 10;9(1):88. doi: 10.1038/s41392-024-01803-6.
Targeted Therapy for Cancers: From Ongoing Clinical Trials to FDA-Approved Drugs.
Choi HY, Chang JE.
Int J Mol Sci. 2023 Sep 3;24(17):13618. doi: 10.3390/ijms241713618.
The evolving landscape of biomarker testing for non-small cell lung cancer in Europe.
Kerr KM, Bibeau F, Thunnissen E, Botling J, Ryška A, Wolf J, Öhrling K, Burdon P, Malapelle U, Büttner R.
Lung Cancer. 2021 Apr;154:161-175. doi: 10.1016/j.lungcan.2021.02.026. Epub 2021 Feb 22.
Degraders in epigenetic therapy: PROTACs and beyond.
Dai XJ, Ji SK, Fu MJ, Liu GZ, Liu HM, Wang SP, Shen L, Wang N, Herdewijn P, Zheng YC, Wang SQ, Chen XB.
Theranostics. 2024 Jan 27;14(4):1464-1499. doi: 10.7150/thno.92526. eCollection 2024.
Targeted Radiotherapeutics from 'Bench-to-Bedside'.
Müller C, Béhé M, Geistlich S, van der Meulen NP, Schibli R.
Chimia (Aarau). 2020 Dec 23;74(12):939-945. doi: 10.2533/chimia.2020.939.
The Ill Returning Traveler.
Rathjen NA, Shahbodaghi SD.
Am Fam Physician. 2023 Oct;108(4):396-403.
The future of general practitioner care in Lower Saxony, Germany: an analysis of actual vs target states using a GIS-based floating catchment area method.
Schoo J, Schüssler F.
Geospat Health. 2025 Jan 23;20(1). doi: 10.4081/gh.2025.1339. Epub 2025 Feb 19.
Emerging Tick-Borne Viruses in the Twenty-First Century.
Mansfield KL, Jizhou L, Phipps LP, Johnson N.
Front Cell Infect Microbiol. 2017 Jul 11;7:298. doi: 10.3389/fcimb.2017.00298. eCollection 2017.
